News and Events

News

All categories

Earnings

Press Release

All years

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

Affimed Reports Second Quarter 2022 Financial Results and Highlights Recent Operational Progress

August 11, 2022

Affimed to Report Second Quarter 2022 Financial Results & Corporate Update on August 11, 2022

August 4, 2022

Affimed Establishes Scientific Advisory Board

June 30, 2022

Affimed Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)

June 10, 2022

Affimed Reports First Quarter 2022 Financial Results and Highlights Recent Operational Progress

June 1, 2022

Affimed Highlights Trial Designs of Three AFM24 Ongoing Clinical Studies at the Annual Meeting of the American Society of Clinical Oncology (ASCO)

May 26, 2022

Affimed to Present at the 2022 Jefferies Healthcare Conference

May 26, 2022

Affimed Announces Annual General Meeting of Shareholders

May 24, 2022

Affimed to Report First Quarter 2022 Financial Results & Corporate Update on June 1, 2022

May 24, 2022

Affimed Presents Data on Innate Cell Engagers AFM24 and AFM28 at 19th Meeting of the Society for Natural Immunity

May 16, 2022

Events

All

Scientific

Investors

28Mar

Innate Killer Summit

March 28 - 30, 2023 (San Diego, USA)

14Apr

AACR Annual Meeting 2023

April 14 - 19, 2023 (Orlando, Florida)

23Apr

EBMT 49th Annual Meeting

April 23 - 26, 2023 (Paris, France)

Webcasts More events

News and Events

News and Events

See what’s new at Affimed

See what’s new at Affimed

News

Affimed Reports Second Quarter 2022 Financial Results and Highlights Recent Operational Progress

Affimed to Report Second Quarter 2022 Financial Results & Corporate Update on August 11, 2022

Affimed Establishes Scientific Advisory Board

Affimed Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)

Affimed Reports First Quarter 2022 Financial Results and Highlights Recent Operational Progress

Affimed Highlights Trial Designs of Three AFM24 Ongoing Clinical Studies at the Annual Meeting of the American Society of Clinical Oncology (ASCO)

Affimed to Present at the 2022 Jefferies Healthcare Conference

Affimed Announces Annual General Meeting of Shareholders

Affimed to Report First Quarter 2022 Financial Results & Corporate Update on June 1, 2022

Affimed Presents Data on Innate Cell Engagers AFM24 and AFM28 at 19th Meeting of the Society for Natural Immunity

Events

Innate Killer Summit

AACR Annual Meeting 2023

EBMT 49th Annual Meeting